OMER
Omeros·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OMER
Omeros Corporation
A biopharmaceutical company that developing small-molecule and protein therapeutics for orphan indications targeting immunologic diseases
201 Elliott Avenue West
, Seattle
, Washington 98119
--
Omeros Corporation was founded in Washington. The company is advancing several development projects focusing on diseases and disorders associated with the complement system, a specialized set of proteins that prevent invasion of pathogens as well as damaged cells in the body and are an important part of the human immune system. When triggered, the various components of the complement synergistically produce an immune response that fights infection and removes damaged or dead cells, maintaining the healthy function of the body's systems. However, dysregulation of the complement system (i.e., overactivation or underactivation) can be harmful and is associated with increased vulnerability to infectious and non-infectious diseases, including autoimmune diseases, chronic inflammation, thrombotic microangiopathy, and cancer.
Earnings Call
Q3/2025
Estimate EPS-0.48
Actual EPS-0.34
Estimate Revenue312.50K
Actual Revenue0
Omeros' Q3 2025: Contradictions Emerge on Narsoplimab Launch Timelines, Fda Review, and Financial Strategy
Nov 14,2025 12:06
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
OMER has released its 2025 Q3 earnings. EPS was reported at -0.34, versus the expected -0.48, beating expectations. The chart below visualizes how OMER has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
